Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00686751 · ClinicalTrials.gov registry record · Phase 2
Immune Effects of Vitamin D in Hemodialysis Patients
A Phase 2 study, sponsored by Renal Research Institute.
- Completed
- Registry status
- Phase 2
- Development phase
- 20
- Enrollment target
NCT00686751 is a Phase 2 study that has completed, run by Renal Research Institute. The registered enrollment target is 20 participants.
The verdict
NCT00686751, a Phase 2 study, has completed, sponsored by Renal Research Institute.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 20 participants
- Enrollment target
Study Summary
The purpose of this study to examine whether vitamin D can reduce the activation of the immune system during dialysis. When activated, the immune cells release certain substances, called cytokines, which can be measured from small blood samples. We want to study to what degree the immune system is activated during a regular dialysis treatment and whether the time point of vitamin D administration, either right before the start or right at the end of a dialysis treatment, has an impact on the activation of the immune system.
Interventions
- DRUG paricalcitol
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2004-12 |
| Est. Completion | 2007-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00686751
The ClinicalTrials.gov registry entry for NCT00686751 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Renal Research Institute, which has 14 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which paricalcitol is the first listed.
NCT00686751 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00686751 about?
NCT00686751 is a clinical study titled "Immune Effects of Vitamin D in Hemodialysis Patients". The purpose of this study to examine whether vitamin D can reduce the activation of the immune system during dialysis. When activated, the immune cells release certain substances, called cytokines, which can be measured from small blood samples. We want to study to what degree the immune system is a...
What is the current status of trial NCT00686751?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2004-12. Estimated completion is 2007-09.
What interventions are being tested in trial NCT00686751?
The interventions under investigation include: paricalcitol (DRUG).
Who is sponsoring clinical trial NCT00686751?
This trial is sponsored by Renal Research Institute, which has 14 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.